echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Alzheimer's & Dementia: The relationship between estrogen and dementia: a nationwide population-based study

    Alzheimer's & Dementia: The relationship between estrogen and dementia: a nationwide population-based study

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dementia is characterized by a gradual decline in cognitive ability and daily activities.
    The two main causes of dementia are Alzheimer's disease (AD) and vascular dementia
    .

    Blood vessel

    Some studies have shown that the use of systemic hormones to treat menopausal vasomotor symptoms is positively correlated with the development of dementia in postmenopausal women
    .


    These studies include the Women’s Health Initiative Memory Study, a randomized, double-blind, placebo-controlled clinical trial that reported that women over 65 years of age doubled their risk of developing dementia after using hormone therapy


    It reported 65 or more years of age women using hormone therapy risk of dementia doubles troubles reported 65 risk over the age of women using hormone therapy troubles dementia doubles

    In addition, other studies have shown that there is a negative or no correlation between hormone therapy and dementia
    .


    The international guidelines on the side effects of hormone therapy (National Institute of Health and Care Excellence [NICE] guidelines) believe that there is a lack of evidence related to dementia, and calls on researchers to conduct more research


    Vaginal estrogen is the main method to treat common symptoms of postmenopause, such as vaginal dryness, irritation, dysuria, and urinary urgency and incontinence, and there have not been any serious adverse events
    .


    However, we currently know little about the dose-dependent effects of vaginal estradiol use and the risk of dementia


    Recently, researchers evaluated the relationship between cumulative doses of vaginal estradiol tablets and dementia in a case-control study nested in a national cohort of Danish women who were age at the start of the study.
    Between the ages of 50 and 60, no systematic hormone therapy is used
    .


    Each case was age-matched with 10 female control groups


    According to the cumulative dose of vaginal estradiol tablets, the risk ratio (HR) of all-cause dementia (A) and Alzheimer's disease (B)

    According to the cumulative dose of vaginal estradiol tablets, the risk ratio (HR) for all-cause dementia (A) and Alzheimer’s disease (B) is based on the cumulative dose of vaginal estradiol tablets, all due to dementia (A) and Alzheimer’s Hazard ratio (HR) of Haimer's disease (B)

    A total of 4574 dementia patients in the study were matched with 45740 control groups
    .


    The results showed that the cumulative use of vaginal estradiol tablets was not associated with all-cause dementia ; the adjusted hazard ratio for low-dose (<750 micrograms) was 1.


    Cumulative use of vaginal estradiol tablets has nothing to do with all-cause dementia.


     

    Original source:

    Original source:

    Nelsan Pourhadi et al.


    Nelsan Pourhadi et al.


     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.